Recuro has acquired MyLegacy, a clinical decision-making support application, which was developed by the Cleveland Clinic Genomic Medicine Institute.
Three things to know:
- MyLegacy will allow the startup to pair automated genetic data gathering with care planning to save time and make more precise decisions, according to a June 22 news release.
- "This acquisition further increases the scope and capabilities of Recuro's digital health platform, pairing automated genetic data gathering with complex care planning to save time, make care more precise and streamline the full continuum of care," the release said.
- It is unclear how much Cleveland Clinic sold MyLegacy for.